Reimbursement decisions: CMS National Coverage Determination (April 2022) restricted aducanumab Medicare coverage to clinical trial enrollment only — a near-zero coverage outcome in practice — citing insufficient evidence of clinical benefit despite FDA approval. Biogen withdrew aducanumab from market Jan 2024.

Evidence span

Reimbursement decisions: CMS National Coverage Determination (April 2022) restricted aducanumab Medicare coverage to clinical trial enrollment only — a near-zero coverage outcome in practice — citing insufficient evidence of clinical benefit despite FDA approval. Biogen withdrew aducanumab from market Jan 2024.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

CMS NCD on monoclonal antibodies for AD, April 7 2022. Biogen aducanumab withdrawal Jan 31 2024.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required